Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses-Reference-Cited by-同舟云学术

Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses

Published:2013-10-18 Issue:1 Volume:17 Page:32-42
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Hill Gregory,Barron Richard,Fust Kelly,Skornicki Michelle E.,Taylor Douglas C. A.,Weinstein Milton C.,Lyman Gary H.

Publisher

Informa Healthcare

Subject

Health Policy

Link

http://www.tandfonline.com/doi/pdf/10.3111/13696998.2013.844160

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2024-02-21

2. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer;Supportive Care in Cancer;2023-09-20

3. Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP;Annals of Hematology;2023-08-21

4. Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study;PLOS ONE;2023-07-17

5. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review;BMC Health Services Research;2022-12-30